Post-earnings recap
Reported
Thu, Jul 23, 2026
EPS actual
$7.32
EPS est.
$6.27
EPS surprise
+16.80%
1-day move
+8.56%
argenx SE reported a strong earnings per share, beating expectations significantly. The positive EPS surprise likely contributed to the stock's 8.56% increase in reaction to the earnings report. However, without revenue figures or management commentary, investors may be cautious about the overall financial health of the company moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $7.32 | N/A | +16.80% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
—
Est. EPS
$4.19
Est. Rev
$1.2B
Impl. Move
±16.2%
argenx SE is a biotechnology company focused on developing innovative therapies for severe autoimmune diseases and cancer. With a market cap of $54 billion, it operates in the Health Care sector, which is increasingly important as demand for advanced treatments grows.
Last quarter
In Q1 2026, argenx reported an EPS of $5.52, surpassing estimates by 6.94%. However, the stock declined by 2.51% the following day, indicating mixed investor sentiment despite the earnings beat.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+236.40%
Avg 1-day reaction
+1.27%
Analysts are cautiously optimistic about argenx's upcoming earnings, given its strong track record of beating EPS estimates. However, the lack of revenue guidance adds uncertainty to investor expectations.
Bull case
If argenx continues its trend of beating EPS estimates and provides positive updates on its pipeline, it could see significant stock appreciation.
Bear case
Conversely, if the company fails to meet expectations or provides disappointing news about its pipeline, it could lead to a sharp decline in stock price.
Key metrics to watch
Earnings Per Share (EPS)
$5.52EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/ARevenue growth reflects the company's ability to expand its market presence and product adoption.
The print will turn on these.
Q1
What will the EPS be for Q2-2026, and will it exceed the expected $5.52?
Given the company's history of beating EPS estimates, this will be a crucial indicator of ongoing financial health.
Q2
What updates can management provide on the progress of its clinical pipeline?
Investors will be keen to understand the potential for new therapies, which could significantly impact future revenue.
Why consensus could be wrong
The Street may underestimate the potential impact of argenx's pipeline advancements, which could lead to stronger-than-expected revenue growth.
Supporting evidence
Historically, argenx has consistently beaten EPS estimates, indicating strong operational execution.
The options market is pricing a larger move than historical averages, suggesting heightened expectations.
Recent positive developments in the biotech sector may bolster investor confidence in argenx.
Key risk
If the company announces a significant breakthrough in its pipeline, it could dramatically shift market sentiment.
Pre-commit to what would confirm each case.
The market is debating whether argenx can maintain its strong earnings performance while navigating challenges in its pipeline.
Bull confirmed if
An EPS of $6.00 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $5.00 would raise concerns about the company's growth trajectory and profitability.
What the market is pricing for the move.
Implied Move
±14.75%
Historical Avg
±5.5%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.
Options are pricing ±14.7% while ARGX has averaged ±5.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
31.0%
Smart-money positioning from the most recent 13F filings.
Institutional
46.07%
of float
Insider
0.00%
of float
Holders
714
institutions
Top Holders· as of Jun 2026
FMR, LLC
5,231,452 sh · $4.9B
8.36%
4.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If argenx beats expectations, history suggests the stock could rise by around 0.79%, confirming the bullish sentiment.
In line / cautious
A result in line with expectations may lead to muted reactions, as investors await further guidance.
Miss
If the company misses EPS estimates, history suggests a potential decline of around 5.01%, reflecting investor disappointment.
The lines on the call that would change the story.
Pipeline Progress
N/AUpdates on the development of new therapies can significantly impact investor sentiment and stock performance.
Price (T.Rowe) Associates Inc
2,678,047 sh · $2.5B
4.28%
-20.6%
Jupiter Topco LLC
2,474,015 sh · $2.3B
3.95%
100.0%
Capital World Investors
2,199,770 sh · $2.0B
3.52%
-2.5%
Artisan Partners Limited Partnership
1,508,778 sh · $1.4B
2.41%
2.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.